Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engageme
AbbVie (NYSE:ABBV) has agreed to acquire Apogee Therapeutics in a cash deal valued at US$10.9b. The transaction focuses on expanding AbbVie's immunology and respiratory disease pipeline with several clinical-stage candidates. The deal is described as AbbVie's largest acquisition in more than five years and includes a premium to Apogee's recent trading levels. AbbVie is a large biopharmaceutical company with a long-standing focus on immunology, oncology, neuroscience, and other specialty...
By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.
The multi-billion-dollar bid could further cement AbbVie’s leading position in the immunology space as competition heats up.
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn't need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.
AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.
Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under...
ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.
AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
AbbVie announced Monday a $10.9 billion plan to acquire immunology-focused Apogee Therapeutics, sending Apogee stock flying.
U.S. stock futures edged higher on Monday as investors monitored corporate dealmaking activity and developments in the biotechnology and cryptocurrency sectors.
AbbVie (NYSE:ABBV) announced on Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) for $10. 9 billion, marking its largest acquisition in more than five years and reinforcing its commitment to expanding its next-generation immunology pipeline.
US futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening. Dow Jones futures were up...
The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis
AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company’s immunology and inflammation portfolio.
June 22 (Reuters) - AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline.
↘️ SpaceX (SPCX): Shares of Elon Musk's rocket company declined 3% premarket, setting up the stock for its third straight session of declines since it began trading publicly a little over a week ago. ↗️ Intel (INTC): Shares in the tech giant climbed 4% premarket.
AbbVie Inc. (NYSE:ABBV) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 16, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over the age of 21. AbbVie said Skinvive […]
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Don't wait too long to get in on these outstanding dividend payers.
The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026
AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup ...